IND for ALA-101 accepted by US FDA
Dr Michael Baker, Managing Director and Chief Executive Officer of Arovella Therapeutics, said: “The team has done an amazing job capturing all of the experimental data and related technical information required for a successful IND submission. To have it accepted by the U.S. FDA demonstrates the capability of our team and the Company’s selected partners, including our manufacturer, Cell Therapies Pty Ltd. We have initiated the activities required for our Human Research Ethics Committee (HREC)submission and clinical trial site selection and activation. Now that the IND is accepted, we look forward to accelerating these activities and taking ALA-101 into the first-in-human phase 1 clinical trial. We are hopeful that ALA-101 will bring meaningful benefit to patients enrolled in the study who would otherwise have no remaining treatment options.”
Share:
More News
“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The FDA’s filing acceptance brings us closer to delivering a new standard-of-care with the
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two